Nalaganje...
Second-line treatment options in hepatocellular carcinoma
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the...
Shranjeno v:
| izdano v: | Drugs Context |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioExcel Publishing Ltd
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6469745/ https://ncbi.nlm.nih.gov/pubmed/31024634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212577 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|